ライフサイエンスコーパス: oncolytic

1 MV-Edm and is highly fusogenic and a potent oncolytic.

2 All viruses demonstrated significant oncolytic abilities independent of MUC1 expression, alth

3 get cells expressing CD4 and retained robust oncolytic activity against HTLV-1 actuated ATL cells.

4 ndent therapeutic barrier and enhance oHSV-1 oncolytic activity in GBM.Significance: These findings s

5 antly, VSV-gp160G effectively exerted potent oncolytic activity in patient-derived ATL transplanted i

6 excluded as being causative for the enhanced oncolytic activity of CD133-targeted viruses.

7 of HD5 in tumor cells diminished the in vivo oncolytic activity of mut-Ad3GFP but not of wt-Ad3GFP.

8 natural neurotoxicity while retaining potent oncolytic activity.

9 nd are superior to Deltagamma(1)34.5 HSVs in oncolytic activity.

10 come the limitations in systemic delivery of oncolytic Ad (oAd) and to specifically target pancreatic

11 immune response against Ad. shMet-expressing oncolytic Ad (oAd; RdB/shMet) complexed with ABP-PEG-HCB

12 he RD Ad, proAdDelta24.GFP, into a fully RC, oncolytic Ad (rAdDelta24) that lyses tumor cells in cult

13 ate that gelatin gel-mediated co-delivery of oncolytic Ad and DCs might be a promising strategy to ef

14 tilized gelatin-based hydrogel to co-deliver oncolytic Ad co-expressing interleukin (IL)-12 and granu

15 icacy of the Ad/PEGbPHF complex platform, an oncolytic Ad expressing VEGF promoter-targeting transcri

16 sify the characteristics of polymer modified oncolytic Ad following each strategy for cancer treatmen

17 However, the systemic injection of oncolytic Ad in clinical applications is restricted due

18 ical trials have been done with either naked oncolytic Ad or combination with chemotherapies.

19 innovative and simple system for delivering oncolytic Ad plasmid DNA with the bioreducible polymers,

20 ioreducible polymer could be used to deliver oncolytic Ad safely and efficiently to treat hepatoma.

21 s such as generation and characterization of oncolytic Ad vectors, can be utilized as an alternative

22 ation of dendritic cells (DCs) combined with oncolytic adenovirus (Ad) expressing antitumor cytokines

23 Oncolytic adenovirus (Ad) vectors present a promising mo

24 We use a newly designed tumor-targeted oncolytic adenovirus (Ad-TD) to deliver non-secreting (n

25 viously designed a conditionally replicative oncolytic adenovirus (CRAd) named Ad-F512 that can targe

26 used ECM-degrading and Wnt signal-disrupting oncolytic adenovirus (oAd/DCN/LRP) to achieve a desirabl

27 models the proinflammatory properties of an oncolytic adenovirus (Onc.Ad) with a helper-dependent Ad

28 implications for clinical use of E3B-deleted oncolytic adenovirus and other E3B-deleted adenovirus ve

29 stify further development of scFv47-modified oncolytic adenovirus and other therapeutics for the trea

30 indicate that this improved stroma-targeted oncolytic adenovirus can override the resistance of mela

31 studies, we show that BM-hMSCs carrying the oncolytic adenovirus Delta-24-RGD prolonged the survival

32 To test the hypothesis, we first constructed oncolytic adenovirus Delta-24-RGDOX expressing the immun

33 hours following in vitro infection with the oncolytic adenovirus dl922-947.

34 The oncolytic adenovirus ICOVIR-15K was engineered to expres

35 Our study has implications for oncolytic adenovirus therapy.IMPORTANCE Previously, it h

36 Although oncolytic adenoviruses (Ads) are an attractive option fo

37 ent a major hurdle to the efficacious use of oncolytic adenoviruses as cancer treatments.

38 egulation of autophagy in cells treated with oncolytic adenoviruses may provide new avenues to improv

39 more effectively activated and redirected by oncolytic adenoviruses that were armed with bispecific T

40 The vast majority of oncolytic adenoviruses used in clinical trials to date h

41 Overall, our results show how arming oncolytic adenoviruses with BiTE can overcome key limita

42 Oncolytic adenoviruses, such as Delta-24-RGD (Delta24RGD

43 and has implications for cancer therapy with oncolytic adenoviruses.

44 results demonstrate that VSV is a promising oncolytic agent against PDA, further studies are needed

45 icular stomatitis virus (VSV) is a promising oncolytic agent against various malignancies.

46 train of Newcastle disease virus (NDV) as an oncolytic agent for cancer therapy has been hampered by

47 yxovirus type 1, NDV, has been an attractive oncolytic agent for cancer virotherapy.

48 atitis virus (VSV) has promise as a systemic oncolytic agent for human cancer therapy.

49 GLV-1h153 is a promising oncolytic agent for the treatment, long-term imaging, an

50 ental MV-NSe, which is currently assessed as oncolytic agent in clinical trials.

51 extensively studied as a vaccine vector and oncolytic agent.

52 sential step toward moving NDV forward as an oncolytic agent.

53 is being evaluated in clinical trials as an oncolytic agent.

54 was aimed at testing the efficacy of IAVs as oncolytic agents for killing human PDA cell lines.

55 practical tool for local delivery of active oncolytic agents to tumor sites.

56 ates have a proven record as clinically used oncolytic agents.

57 ificantly inhibited tumor growth in vivo via oncolytic and apoptotic effects, and (Ad5/3-hTERT-E1A-hC

58 and for applications as a safety switch for oncolytic and live vaccine viruses.

59 combinant virus merits further study for its oncolytic and vaccine potential.

60 better known as tools for gene delivery and oncolytic anticancer therapy.

61 Clinical trials of oncolytic attenuated measles virus (MV) are ongoing, but

62 ucible VACV promoter for use in vaccines and oncolytic cancer therapies.

63 on of VSV-LASV-GPC as a safe and efficacious oncolytic chimeric virus within the brain.

64 Ad5-E1/AFP-E3/NIS, a significantly enhanced oncolytic effect was observed after intravenous applicat

65 tion of these agents (CAd-VECPDL1) exhibited oncolytic effects with production of PD-L1 mini-body loc

66 nd ligand-displaying viruses displayed equal oncolytic efficacies in a syngeneic mouse myeloma model.

67 data indicate that VSV-gp160G exerts potent oncolytic efficacy against CD4(+) malignant cells and ei

68 HD5 expression in cancer cells decreases the oncolytic efficacy of a serotype 5-based adenovirus vect

69 es is paramount to realizing the exceptional oncolytic efficacy of NDV.

70 ent VSVs without perturbing viral growth and oncolytic efficacy.

71 the family Poxviridae and possess promising oncolytic features.

72 For oncolytic gene therapy for cancer, where replication-com

73 fection and spread of replication-competent, oncolytic HAdV type 3 (HAdV3).

74 Oncolytic herpes simplex virus (oHSV) selectively replic

75 Oncolytic viruses, including oncolytic herpes simplex virus (oHSV), have produced pro

76 nt mice, and tested the fate and efficacy of oncolytic herpes simplex virus (oHSV)-armed mesenchymal

77 ects and replicates similarly to its unarmed oncolytic herpes simplex virus counterpart in mouse 005

78 Oncolytic herpes simplex virus G47Delta, which carried t

79 is model, we tested a genetically engineered oncolytic herpes simplex virus that is armed with an imm

80 means substantially increased replication of oncolytic herpes simplex virus type 1 (oHSV).

81 Herein we demonstrate that oncolytic herpes simplex virus-1 (HSV-1) potently activa

82 ) but not 76-9 (MHC I low) tumors respond to oncolytic herpes simplex virus-1 (oHSV-1) and PD-1 block

83 Food and Drug Administration approval of the oncolytic herpesvirus talimogene laherparepvec in advanc

84 r the development of more effective targeted oncolytic HSV vectors.

85 g the tumor-specific spreading of retargeted oncolytic HSV vectors.

86 on or deletion mutations and to construct an oncolytic HSV-1 that utilizes the disialoganglioside GD2

87 nicity, the gamma34.5 gene is deleted in all oncolytic HSVs (oHSVs) currently in clinical trial for t

88 ead compound for further evaluation as novel oncolytic immunotherapeutic.

89 Oncolytic immunotherapies represent a new promising stra

90 EC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicat

91 T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benef

92 Oncolytic immunotherapy with PVSRIPO, the type 1 live-at

93 immune cells that participate in clearing an oncolytic infection in glioma, we used flow cytometry an

94 Here, we describe oncolytic measles viruses (MV) retargeted to CD133.

95 ant role to play in the antitumor effects of oncolytic MV.

96 and T cells in the clearance and efficacy of oncolytic MYXV from gliomas.

97 genetics, we have generated a lead candidate oncolytic NDV based on the mesogenic NDV-73T strain that

98 tion and characterization of a highly potent oncolytic NDV variant that is unlikely to cause Newcastl

99 served in several paramyxoviruses.IMPORTANCE Oncolytic Newcastle disease virus (NDV) could establish

100 hedding, increasing its safety profile as an oncolytic, or might have any effect on CD46 binding, we

101 gnificantly, perioperative administration of oncolytic parapoxvirus ovis (ORFV) and vaccinia virus ca

102 Oncolytic peptides represent a promising new strategy wi

103 In our efforts to develop oncolytic peptides, we identified a series of chemically

104 Seneca Valley virus (SVV) is an oncolytic picornavirus with selective tropism for neuroe

105 select 'winners' from a burgeoning number of oncolytic platforms and engineered derivatives, to trans

106 ised CD46 binding and greatly diminished the oncolytic potency of these viruses on human cancer cells

107 neurovirulence of VSV without perturbing its oncolytic potency.

108 rus could be eliminated without blocking its oncolytic potential in the brain by replacing the neurot

109 Here we hypothesized that an oncolytic poxvirus would attract T cells into the tumour

110 t lyses tumor cells in culture and generates oncolytic progeny virions.

111 tion of ICOVIR-15K-cBiTE, which retained its oncolytic properties in vitro cBiTE expression and secre

112 nd to limit both the immune presentation and oncolytic properties of these vectors.

113 ing HSV1 amplicon leads to generation of RC, oncolytic rAdDelta24.

114 on can be applied to switch RD Ad into fully oncolytic RC Ad for tumor therapy and is potentially app

115 onstructs, and a tet operator sequence) into oncolytic recombinant vaccinia viruses (rVACV), which we

116 unogold labeling study of internalization of oncolytic reovirus in human dendritic cells, in a cryo-e

117 rain of vesicular stomatitis virus (VSV), an oncolytic rhabdovirus that bound MDSCs and used them as

118 l tropism for CD46 which is the basis of its oncolytic specificity.

119 ion but that could be "switched" into an RC, oncolytic state when needed might represent an advance i

120 ll as the application of measles virus as an oncolytic therapeutic.

121 They are also being developed as oncolytic therapeutics and as gene therapy vectors.

122 the tumor-killing activity of tumor-targeted oncolytic therapeutics.

123 ighly desirable as either vaccine vectors or oncolytic therapies, and would likely be better tolerate

124 gies and improvement of lytic-phase-directed oncolytic therapies, therefore, hinge on gaining a bette

125 sidered vectors for recombinant vaccines and oncolytic therapies.

126 t leads on devising methods to improve viral oncolytic therapies.

127 n also directly impacts the success of viral oncolytic therapy for EBV cancers, yet determinants of s

128 s viral persistence and the effectiveness of oncolytic therapy for EBV(+) cancers.

129 in EBV biology and guide efforts to improve oncolytic therapy for EBV-associated cancers.

130 -Barr virus (EBV)-infected tumor cells using oncolytic therapy is the presence of a substantial fract

131 inducers of the lytic cycle are desired for oncolytic therapy.

132 er, these effects were further enhanced when oncolytic treatment was combined with immunogenic chemot

133 hat VACV and MYXV can exhibit very different oncolytic tropisms against some cancerous human leukocyt

134 ture and inhibits intravenously administered oncolytic vaccinia delivery to and consequent spread wit

135 of resistance to immunotherapies, including oncolytic vaccinia virotherapy.

136 efficacy of a CXCR4 antagonist expressed by oncolytic vaccinia virus (OVV) against an invasive varia

137 e in colon and ovarian cancer models that an oncolytic vaccinia virus attracts effector T cells and i

138 ere that CXCR4 antagonist expression from an oncolytic vaccinia virus delivered intravenously to mice

139 oxicity, and we show for the first time that oncolytic vaccinia virus markedly increases NK cell acti

140 only one or two genes into the genome of an oncolytic vaccinia virus strain.

141 iangiogenic single chain antibodies by using oncolytic vaccinia virus strains to enhance their therap

142 We show here that this expanded tropism of oncolytic vaccinia virus to the endothelial compartment

143 We report here that the engineered oncolytic vaccinia virus VVWR-TK(-)RR(-)-Fcu1 can induce

144 rapeutic efficacy of a replication-competent oncolytic vaccinia virus, GLV-1h153, carrying human sodi

145 ized features of the antitumor properties of oncolytic vaccinia viruses, all of which can be amplifie

146 r to conventional attenuated HSV vaccine and oncolytic vectors without sacrificing safety.

147 the safety and efficacy of viral vaccine and oncolytic vectors.

148 This study focuses on oncolytic vesicular stomatitis virus (VSV) against pancr

149 re sensitive and cells that are resistant to oncolytic vesicular stomatitis virus (VSV).

150 IFN-alpha2a and IFN-beta, in protection from oncolytic vesicular stomatitis virus.

151 We are developing oncolytic vesicular stomatitis viruses (VSVs) for system

152 Oncolytic viral (OV) therapy, which uses genetically eng

153 plicating adenovirus vectors for vaccines or oncolytic viral targeting of neoplastic cells.

154 ), are powerful tools for the development of oncolytic viral therapies and elicit superior immune res

155 Oncolytic viral therapy and photodynamic therapy are pot

156 The basis for oncolytic viral therapy is the selective replication of

157 the first in-vitro study to combine reovirus oncolytic viral therapy with PpIX-mediated photodynamic

158 for laser-induced thermotherapy and enhanced oncolytic viral therapy.

159 ation vaccine programs and as a safeguard in oncolytic viral therapy.

160 hogenesis and foster engineering of improved oncolytic viral vectors.

161 ridae, are both currently being developed as oncolytic virotherapeutic agents.

162 , a Leporipoxvirus, is being developed as an oncolytic virotherapeutic for the treatment of a variety

163 have supported the growing appreciation that oncolytic virotherapies primarily act as immunotherapies

164 at IAVs may hold promise as future agents of oncolytic virotherapy against pancreatic ductal adenocar

165 nvestigated as candidates for human systemic oncolytic virotherapy and gene therapy applications.

166 enoviral vectors for combination of systemic oncolytic virotherapy and NIS-mediated radiotherapy.

167 ibes poxviruses that are being developed for oncolytic virotherapy and summarizes the outcomes of bot

168 vestigated as a candidate for human systemic oncolytic virotherapy applications.

169 The first oncolytic virotherapy employing HSV-1 (oHSV-1) was appro

170 Oncolytic virotherapy exploits live viruses with selecti

171 Both anti-PD1/PD-L1 therapy and oncolytic virotherapy have demonstrated promise, yet hav

172 ategy to enhance the therapeutic efficacy of oncolytic virotherapy in glioblastoma.

173 how to safely improve the efficacy of local oncolytic virotherapy in patients whose tumors are chara

174 However, translation of VSV oncolytic virotherapy into the clinic is being hindered

175 Oncolytic virotherapy is a promising approach for the tr

176 Oncolytic virotherapy is an effective immunotherapeutic

177 Oncolytic virotherapy is an emerging therapeutic for the

178 Oncolytic virotherapy is an emerging treatment modality

179 emonstrating superior efficacy when poxvirus oncolytic virotherapy is combined with conventional ther

180 These findings suggest that oncolytic virotherapy may improve the efficacy of anti-P

181 Oncolytic virotherapy of cancer can greatly benefit from

182 athogenic IAVs may prove to be effective for oncolytic virotherapy of PDA and provide grounds for fur

183 Oncolytic virotherapy represents an attractive option fo

184 The key role of type 1 IFN pathway in oncolytic virotherapy was also highlighted, as we observ

185 and their stromal microenvironment, we used oncolytic virotherapy with a CXCR4 antagonist to target

186 hase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on c

187 erapeutic response and potential toxicity of oncolytic virotherapy, a noninvasive, deep-tissue imagin

188 cide gene therapy, genetic immunotherapy and oncolytic virotherapy, and we have attributed the challe

189 safety as well as the therapeutic outcome of oncolytic virotherapy.

190 indispensable for realizing the potential of oncolytic virotherapy.

191 nisms could be a considerable improvement in oncolytic virotherapy.

192 d breast tumors, rendering them resistant to oncolytic virotherapy.

193 es with BiTE can overcome key limitations in oncolytic virotherapy.

194 lar mechanisms of resistance of some PDAs to oncolytic virotherapy.

195 ay can significantly improve outcomes during oncolytic virotherapy.

196 n pathogen but also as a promising agent for oncolytic virotherapy.

197 Drug Administration approval of immunogenic oncolytic virus (OV) has opened a new era in the treatme

198 Farrar et al demonstrate that modifying an oncolytic virus (OV) so that it produces excess protein

199 Oncolytic virus (OV) therapies of cancer are based on th

200 Oncolytic virus (OV) therapy has emerged as a novel tool

201 ng VSV attachment and replication.IMPORTANCE Oncolytic virus (OV) therapy is an anticancer approach t

202 es of a hypoxia-regulated, prostate-specific oncolytic virus (OV) to prostate tumors.

203 and cancer cells leads to enhanced growth of oncolytic virus (OV)-based therapeutics.

204 icular stomatitis virus (VSV) is a promising oncolytic virus (OV).

205 s being developed presently as a therapeutic oncolytic virus [talimogene laherparepvec (T-VEC)].

206 ation that could be used in both vaccine and oncolytic virus applications.

207 Engineering an oncolytic virus armed with a CXCR4 antagonist represents

208 tacles, we have combined CAR-T cells with an oncolytic virus armed with the chemokine RANTES and the

209 Newcastle disease virus (NDV) is an oncolytic virus being developed for the treatment of can

210 nt tumor cell killing makes it an attractive oncolytic virus candidate that may provide clinical bene

211 an alternative region of dosing space (lower oncolytic virus dose, higher dendritic cell dose) for wh

212 -FH has significant advantages over MV as an oncolytic virus due to its higher viral yield, faster re

213 t that intratumoral immunomodulation with an oncolytic virus expressing a rationally selected ligand

214 um iodide symporter (NIS) (VSV-mIFNbeta-NIS) oncolytic virus has significant antileukemia activity, w

215 the presumed advantages for using VSV as an oncolytic virus is that human infections are rare and pr

216 fects either on the cancer patient or on the oncolytic virus itself if they are expressed at the wron

217 VSV is one oncolytic virus out of an arsenal of potential candidate

218 , but antibody neutralization of circulating oncolytic virus particles remains a formidable barrier.

219 Implications for the initial dynamics of oncolytic virus spread through tumors are discussed.

220 e preclinical studies, melanin overproducing oncolytic virus strains might be used in clinical trials

221 Our results suggest that ZIKV is an oncolytic virus that can preferentially target GSCs; thu

222 utant HSV1716 is a conditionally replicating oncolytic virus that selectively replicates in and lyses

223 We explored the use of oncolytic virus therapy against glioblastoma with Zika v

224 this approach might increase the efficacy of oncolytic virus therapy and to identify gaps in knowledg

225 Oncolytic virus therapy is being evaluated in clinical t

226 A major challenge to oncolytic virus therapy is that individual cancers vary

227 One of the several impediments to effective oncolytic virus therapy of cancer remains a lack of tumo

228 randomized trial to evaluate addition of an oncolytic virus to a checkpoint inhibitor.

229 human T lymphocytes effectively deliver live oncolytic virus to human multiple myeloma cells, thus au

230 s, thus augmenting GVM by transfer of active oncolytic virus to residual cancer cells.

231 inistering a single dose of TGFbeta prior to oncolytic virus treatment of glioblastoma can transientl

232 e enhanced functional studies, generation of oncolytic virus vectors, development of delivery platfor

233 e cytokine IL15, reasoning that the modified oncolytic virus will both have a direct lytic effect on

234 Here, we report an approach to arm an oncolytic virus with CD40 ligand (CD40L) to stimulate be

235 Our data demonstrate that combining an oncolytic virus with tumor-targeting immune checkpoint m

236 icacy of talimogene laherparepvec (T-VEC; an oncolytic virus) in combination with ipilimumab (a cytot

237 RI) system to direct macrophages carrying an oncolytic virus, Seprehvir, into primary and metastatic

238 ers that can bind noncovalently to an intact oncolytic virus, vaccinia virus (VACV), which can select

239 Here, we took a promising oncolytic virus, vesicular stomatitis virus (VSV), and t

240 is work, we selected DNA aptamers against an oncolytic virus, vesicular stomatitis virus (VSV), to pr

241 s aimed at promoting the optimum efficacy of oncolytic virus-based anticancer immunotherapies.

242 ating older approaches, such as vaccines and oncolytic virus-based treatments-are being investigated.

243 ise both as an immunization vector and as an oncolytic virus.

244 e promise both as a vaccine vector and as an oncolytic virus.

245 ll positioned for clinical development as an oncolytic virus.

246 to the burgeoning fields of cancer-killing (oncolytic) virus therapy with vaccinia virus (VACV).

247 Oncolytic viruses (OV) and ultrasound-enhanced drug deli

248 As cancer treatment tools, oncolytic viruses (OV) have yet to realize what some see

249 Oncolytic viruses (OV) preferentially kill cancer cells

250 Oncolytic viruses (OVs) are emerging as important agents

251 ng immunoshielding agents that could protect oncolytic viruses (OVs) from neutralizing antibodies (nA

252 be used to study therapies involving various oncolytic viruses and chemotherapeutics, with the goal o

253 vides a new rationale for the combination of oncolytic viruses and chemotherapy.

254 to maximize the immunotherapeutic action of oncolytic viruses and clinical confirmation of a critica

255 subject to treatment with immunostimulatory oncolytic viruses and dendritic cell vaccines.

256 Understanding the interactions between oncolytic viruses and the innate immune system will faci

257 n comparison with other clinically evaluated oncolytic viruses and to PD-1 blockade, LCMV treatment s

258 Oncolytic viruses are an active area of clinical researc

259 These studies indicate that oncolytic viruses are remarkably safe and more efficacio

260 Oncolytic viruses based on adenovirus type 5 (Ad5) have

261 oregional cancer therapeutic approaches with oncolytic viruses can lead to systemic anti-tumour immun

262 Oncolytic viruses designed to attack malignant cells can

263 Both HP-NAP protein and oncolytic viruses encoding HP-NAP have been suggested as

264 Athough the clinical efficacy of oncolytic viruses has been demonstrated for local treatm

265 Clinical and/or preclinical studies on oncolytic viruses have revealed that the candidate virus

266 Oncolytic viruses hold promise for the treatment of canc

267 them an advantage over interferon-sensitive oncolytic viruses in tumors showing residual interferon

268 The cancer-selective nature of some oncolytic viruses is based on the impaired innate immuni

269 ting of tumor cells by replication-competent oncolytic viruses is considered indispensable for realiz

270 Yet off-target infections by oncolytic viruses may increase virus production, further

271 Oncolytic viruses obliterate tumor cells in tissue cultu

272 Oncolytic viruses offer the attractive therapeutic combi

273 Oncolytic viruses pose many questions in their use in ca

274 As such, oncolytic viruses represent a promising cancer-specific

275 Oncolytic viruses selectively lyse tumor cells, disrupt

276 Oncolytic viruses such as vesicular stomatitis virus (VS

277 the state of current research on the use of oncolytic viruses targeted to stem cells as a potential

278 of new therapeutic genes into the genome of oncolytic viruses that could not have been tested otherw

279 adenovirus from the mechanism used by other oncolytic viruses to induce autophagy and provides a new

280 method to overcome this challenge is to use oncolytic viruses to induce secondary antitumor immune r

281 r than completely eliminating the ability of oncolytic viruses to infect and lyse normal cells could

282 A workshop "Targeting Oncolytic Viruses to Tumor Stem Cells," organized by the

283 ons may allow for the generation of modified oncolytic viruses with greater selective tumor cell repl

284 mathematical framework for assessing whether oncolytic viruses with reduced tumor-specificity can mor

285 on-competent viruses that kill cancer cells (oncolytic viruses).

286 ividual cancers vary in their sensitivity to oncolytic viruses, even when these cancers arise from th

287 ividual cancers vary in their sensitivity to oncolytic viruses, even when these cancers arise from th

288 Oncolytic viruses, including oncolytic herpes simplex vi

289 Recently, however, many oncolytic viruses, including reovirus, have been reporte

290 ancer stemlike cells, cell cycle regulation, oncolytic viruses, new radiotherapy techniques, and immu

291 Unlike many other oncolytic viruses, we found no evidence that impairment

292 ividual cancers vary in their sensitivity to oncolytic viruses.

293 great deal of progress in the development of oncolytic viruses.

294 h for new generations of efficiency-enhanced oncolytic viruses.

295 m other viruses show promise as vaccines and oncolytic viruses.

296 with IFN-alpha2a may enhance selectivity of oncolytic VSV therapy for HNSCC by inhibiting VSV replic

297 en fluorescent protein (VSV-GFP), and a safe oncolytic VSV-DeltaM51-GFP, against five mouse PDA cell

298 r the future development of fully retargeted oncolytic VSVs.

299 ndothelial growth factor A (VEGF-A) augments oncolytic VV cytotoxicity.

300 and the development of future generations of oncolytic VV in combination with conventional or biologi